Drug eluting balloons for de novo coronary lesions - a systematic review and meta-analysis

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Fröhlich, Georg M ^a   Lansky, Alexandra J ^b   Ko, Dennis T ^c   Archangelidi, Olga ^d   De Palma, Rodney ^a   Timmis, Adam ^e   Meier, Pascal ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

Coronary artery disease; Drug eluting balloon; Percutaneous coronary intervention; Stents

Indexed keywords

CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

ARTICLE; BALLOON OCCLUSION; BARE METAL STENT; CEREBRAL REVASCULARIZATION; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING BALLOON; DRUG ELUTING STENT; EMBASE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; MEDLINE; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW; TARGET LESION REVASCULARIZATION; TREND STUDY;

CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEMS; HUMANS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84877638855     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-123     Document Type: Article

References (40)

1. Chan PS, Patel MR, Klein LW, Krone RJ, Dehmer GJ, Kennedy K, Nallamothu BK, Weaver WD, Masoudi FA, Rumsfeld JS, Brindis RG, Spertus JA. Appropriateness of percutaneous coronary intervention. JAMA 2011, 306:53-61. 10.1001/jama.2011.916, 3293218, 21730241.
2. Meier P, Timmis A. Almanac 2012: interventional cardiology: the national society journals present selected research that has driven recent advances in clinical cardiology. Heart 2012, 98:1701-1709. 10.1136/heartjnl-2012-302569, 22942292.
3. Meier P, Lansky AJ. Optimal duration of clopidogrel therapy: the shorter the longer. Eur Heart J 2012, [Epub ahead of print.].
4. Cassese S, Byrne RA, Tada T, King LA, Kastrati A. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J 2012, 33:3078-3087. 10.1093/eurheartj/ehs318, 23091199.
5. Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand SL, Rumsfeld JS, Messenger JC, Yeh RW. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med 2012, 172:1145-1152.
6. Sarno G, Lagerqvist B, Frobert O, Nilsson J, Olivecrona G, Omerovic E, Saleh N, Venetzanos D, James S. Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012, 33:606-613. 10.1093/eurheartj/ehr479, 22232428.
7. Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, Dudek D, Smits PC, Koolen J, McClean D, Dorange C, Veldhof S, Rapoza R, Onuma Y, Bruining N, Ormiston JA, Serruys PW. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?. Eur Heart J 2012, 33:1325-1333. 10.1093/eurheartj/ehr466, 22507972.
8. Indermühle A, Bahl R, Lansky AJ, Fröhlich G, Knapp G, Timmis A, Meier P. Drug eluting balloon-angioplasty for instent-restenosis - a systematic review and meta-analysis of randomized controlled trials. Heart 2013, in press.
9. Ali RM, Degenhardt R, Zambahari R, Tresukosol D, Ahmad WA, Kamar H, Kui-Hian S, Ong TK, bin Ismail O, bin Elis S, Udychalerm W, Ackermann H, Boxberger M, Unverdorben M. Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus. EuroIntervention 2011, 7(suppl K):K83-92.
10. Belkacemi A, Agostoni P, Nathoe HM, Voskuil M, Shao C, Van Belle E, Wildbergh T, Politi L, Doevendans PA, Sangiorgi GM, Stella PR. First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. J Am Coll Cardiol 2012, 59:2327-2337. 10.1016/j.jacc.2012.02.027, 22503057.
11. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535. 10.1136/bmj.b2535, 2714657, 19622551, PRISMA Group.
12. Tricco AC, Straus SE, Moher D. How can we improve the interpretation of systematic reviews?. BMC Med 2011, 9:31. 10.1186/1741-7015-9-31, 3072347, 21450084.
13. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999, 282:1054-1060. 10.1001/jama.282.11.1054, 10493204.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188. 10.1016/0197-2456(86)90046-2, 3802833.
15. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 2009, 172:137-159. 10.1111/j.1467-985X.2008.00552.x, 2667312, 19381330.
16. Sankey S, Weissfeld L, Fine M, Kapoor W. An assesment of the use of of the continuity correction for sparse data in metanalysis. Commun Stat - Simul C 1996, 25:1031-1056.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558. 10.1002/sim.1186, 12111919.
18. Meier P, Hemingway H, Lansky AJ, Knapp G, Pitt B, Seiler C. The impact of the coronary collateral circulation on mortality: a meta-analysis. Eur Heart J 2012, 33:614-621. 10.1093/eurheartj/ehr308, 21969521.
19. Hamm CW. PEPCAD-3: Paclitaxel-Coated-Balloon/Stent System Misses Mark in De Novo Coronary Lesions (abstract) 2009, Orlando, FL: American Heart Association, Accessed via http://www.theheart.org/article/1021669/print.do, accessed on 28. Dec 2012.
20. Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S, Limbruno U. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 2010, 96:1291-1296. 10.1136/hrt.2010.195057, 20659948.
21. Wohrle J, Birkemeyer R, Markovic S, Nguyen TV, Sinha A, Miljak T, Spiess J, Rottbauer W, Rittger H. Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. Heart 2011, 97:1338-1342. 10.1136/hrt.2011.226563, 21617163.
22. Herdeg C, Gohring-Frischholz K, Haase KK, Geisler T, Zurn C, Hartmann U, Wohrle J, Nusser T, Dippon J, May AE, Gawaz M. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation. Circ Cardiovasc Interv 2009, 2:294-301. 10.1161/CIRCINTERVENTIONS.108.827865, 20031731.
23. R Development Core Team R: A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing, http://www.R-project.org, R Development Core Team.
24. Stella PR, Belkacemi A, Dubois C, Nathoe H, Dens J, Naber C, Adriaenssens T, van Belle E, Doevendans P, Agostoni P. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial. Catheter Cardiovasc Interv 2012, 80:1138-1146. 10.1002/ccd.23499, 22422607.
25. Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F, Marchese A, Tespili M, Presbitero P, Sgueglia GA, Buffoli F, Tamburino C, Varbella F, Menozzi A. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol 2012, 60:2473-2480. 10.1016/j.jacc.2012.09.020, 23158530.
26. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D, Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI) Guidelines on myocardial revascularization. Eur Heart J 2010, 31:2501-2555. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI).
27. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007, 370:937-948. 10.1016/S0140-6736(07)61444-5, 17869634.
28. Stenestrand U, James SK, Lindback J, Frobert O, Carlsson J, Schersten F, Nilsson T, Lagerqvist B. group SSs: Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2010, 31:177-186. 10.1093/eurheartj/ehp424, 19903684.
29. Kastrati A, Schomig A, Dirschinger J, Mehilli J, Dotzer F, von Welser N, Neumann FJ. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease, ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation 2000, 102:2593-2598. 10.1161/01.CIR.102.21.2593, 11085962.
30. Hara H, Nakamura M, Palmaz JC, Schwartz RS. Role of stent design and coatings on restenosis and thrombosis. Adv Drug Deliv Rev 2006, 58:377-386. 10.1016/j.addr.2006.01.022, 16650911.
31. Sternberg K, Grabow N, Petersen S, Weitschies W, Harder C, Ince H, Kroemer HK, Schmitz KP. Advances in coronary stent technology - active drug-loaded stent surfaces for prevention of restenosis and improvement of biocompatibility. Curr Pharm Biotechnol 2013, 14:76-90.
32. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol 2010, 56(10 Suppl):S43-78.
33. Van Buuren F, Dahm JB, Horskotte D. Stent restenosis and thrombosis: etiology, treatment, and outcomes. Minerva Med 2012, 103:503-511.
34. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012, 379:1393-1402. 10.1016/S0140-6736(12)60324-9, 22445239.
35. Lupi A, Rognoni A, Secco GG, Lazzero M, Nardi F, Fattori R, Bongo AS, Agostoni P, Sheiban I. Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5834 patients. Eur J Prev Cardiol 2012, [Epub ahead of print.].
36. King L, Byrne RA, Mehilli J, Schomig A, Kastrati A, Pache J. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial. Catheter Cardiovasc Interv 2013, 81:E23-28. 10.1002/ccd.24375, 22431239.
37. Cortese B, Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. Int J Cardiol 2012, 161:4-12. 10.1016/j.ijcard.2011.08.855, 21955612.
38. Pósa A, Nyolczas N, Hemetsberger R, Pavo N, Petnehazy O, Petrasi Z, Sangiorgi G, Gyöngyösi M. Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries. Catheter Cardiovasc Interv 2010, 76:395-403. 10.1002/ccd.22468, 20839356.
39. Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, Tanabe K, Morino Y, Akasaka T, Takatsu Y, Nishikawa H, Yamamoto Y, Nakagawa Y, Hayashi Y, Iwabuchi M, Umeda H, Kawai K, Okada H, Kimura K, Simonton CA, Kozuma K, RESET Investigators Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). Circulation 2012, 126:1225-1236. 10.1161/CIRCULATIONAHA.112.104059, 22824435, RESET Investigators.
40. Cremers B, Toner JL, Schwartz LB, von Oepen R, Speck U, Kaufels N, Clever YP, Mahnkopf D, Bohm M, Scheller B. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. Clin Res Cardiol 2012, 101:469-476. 10.1007/s00392-012-0415-7, 22293991.